Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/16/2025

Chemotherapy Administration

Introduction to Chemotherapy Regimens

  • Infusional administration of 5-FU is recommended by the National Comprehensive Cancer Network and the American Cancer Society, as it has a lower peak concentration but longer exposure, resulting in less toxicity while maintaining efficacy in patients with colorectal cancer 1, 2

Administration Schedules

  • The European Society for Medical Oncology and the American Society of Clinical Oncology recommend the following administration schedules:

Patient Considerations

  • The National Comprehensive Cancer Network recommends considering DPYD genotyping to guide dose adjustments and reduce toxicity in patients with DPD enzyme deficiency, particularly in elderly or frail patients 3
  • The European Society for Medical Oncology suggests starting with single-agent fluoropyrimidine therapy or dose-reduced combination regimens for elderly or frail patients 2

Adjuvant and Metastatic Therapy

  • The American Joint Committee on Cancer recommends a 6-month course of 5-FU/leucovorin as standard adjuvant therapy in stage III colon cancer, with infusional regimens preferred over bolus 4
  • The European Society for Medical Oncology suggests that infusional 5-FU in combination regimens (FOLFOX, FOLFIRI) provides higher response rates and better survival than bolus 5-FU alone in patients with metastatic disease 2

Medication Safety

  • The National Comprehensive Cancer Network recommends limiting chemotherapy orders to 24-hour units to minimize medication errors 1
  • Standard chemotherapy regimens for colorectal cancer include:

    Regimen Dosage
    mFOLFOX6 Oxaliplatin 85 mg/m² IV over 2 hours on day 1, leucovorin 400 mg/m² IV over 2 hours on day 1, 5-FU 400 mg/m² IV bolus on day 1, followed by 1,200 mg/m²/day continuous infusion for 2 days
    CAPOX (XELOX) Oxaliplatin 130 mg/m² IV on day 1 and capecitabine 1,000 mg/m² twice daily for 14 days, every 3 weeks
    FOLFIRI Irinotecan 180 mg/m² IV over 90 minutes on day 1, leucovorin 400 mg/m² IV over 2 hours on day 1, 5-FU 400 mg/m² IV bolus on day 1, followed by 1,200 mg/m²/day continuous infusion for 2 days
  • For patients at high risk of behavioral changes, the American Society of Clinical Oncology recommends considering FOLFOX or fluoropyrimidine monotherapy, while for patients with low risk, any standard regimen (FOLFOX, FOLFIRI) can be used based on disease characteristics 5, 2
  • Prophylactic measures, such as aggressive hydration and electrolyte management, and early intervention for diarrhea with loperamide, can help prevent behavioral changes in patients receiving irinotecan-containing regimens, as recommended by the National Comprehensive Cancer Network 5, 2
  • Regular assessment of cognitive function and behavior, as well as electrolyte monitoring, especially during episodes of diarrhea, is crucial in managing behavioral changes in patients receiving chemotherapy, as recommended by the American Society of Clinical Oncology 5, 2
  • Dose reduction or interruption, and consideration of switching from FOLFIRI to FOLFOX, may be necessary if severe behavioral changes occur, as recommended by the European Society for Medical Oncology 5, 2